Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News on Pharma

FDA panel weighs moving opioid antidote over the counter

U.S. health advisers are weighing whether the overdose-reversal drug naloxone should be made available as an over-the-counter medication

The Independent UK

Prepping for a new post-Roe reality

A decision on a lawsuit in Texas could lead to nationwide mifepristone ban

Salon

The administration's next crack at lower drug prices

The Biden administration unveiled three drug payment programs Tuesday aimed at helping reduce patients' out-of-pocket costs.

Axios

From analysis to the latest developments in health,
read the most diverse news in one place.

Edinburgh-based health tech company Clevermed acquired by hospital software specialist System C

Move will support growth of flagship product BadgerNet,

Insider UK

CSL grows first-half profit 10pct to $2.6 billion

CSL has beaten first-half earnings expectations thanks to its vaccine business and contributions from its new iron deficiency therapy company.

AAP

The Best Stock to Invest $1,000 in Right Now

Pfizer (PFE) played a pivotal role in developing vaccines and pills that helped the world return to normal from the COVID-19 pandemic. The company reported record revenue and earnings in fiscal 2022. Given the company’s solid growth prospects, it could be wise to invest in the stock right now. Keep…

StockNews.com

40 million would lose abortion access if court blocks pill, study shows

163% more women would lose access to abortion care if the FDA's approval of mifepristone is revoked.

Axios

Read news from The Economist, FT, and more,
with one subscription

Take AstraZeneca’s warning seriously. The UK is missing out in life sciences

Big pharma has choices about where to make new investments and, increasingly it seems, it is not choosing Britain

The Guardian - UK

Centene Corp. settles for $215 million on California Medicaid overbilling accusations

More than 20 states are investigating or have investigated Centene’s Medicaid pharmacy billing. The company also has agreed to pay settlements to at least 16 other states, including Illinois and Indiana.

Chicago Sun-Times

Pharmac to get one-time $66m boost

The national drug-buying agency will get an extra $66 million in 2023 in a one-off cash injection, according to documents reviewed by Newsroom.

Newsroom.co.nz

Shield Therapeutics revenues boosted by US sales of iron deficiency pills

The pharmaceuticals firm recently joined forced with Pennsylvania-based Viatris to tackle the American market

Birmingham Post

CVS buys Chicago-based Oak Street Health for $10.6B

Oak Street Health runs primary care centers mostly for lower-to-middle income people with Medicare Advantage plans.

Chicago Sun-Times

Glasgow biopharmaceuticals firm hires new chief executive

University spin-out takes on new leadership as it looks towards international growth

Insider UK

1 Medical Stock to Get Bullish on Right Now

Medical stock Zoetis (ZTS) has witnessed steady growth despite the market turbulence in the past few months. Moreover, Wall Street analysts expect the stock to soar further. So, considering its robust fundamentals, ZTS might be worth buying now. Keep reading.

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

Pfizer’s Susan Rienow: from Covid to fighting the ‘silent pandemic’

The pharma giant’s UK chief is adding the company’s voice to scientists’ warnings of the dangers of antibacterial resistance

Insider UK

Nodus Oncology secures £2.4 million investment

Edinburgh-based start-up will now be able to accelerate development of its life sciences technology

Daily Record

Workers resume strike action as union admit dispute could drag on

Unite chiefs say their members are determined to get 'what they are owed' in bonus payments row.

StockNews.com

Want to Get Richer in 2023? Try This Medical Stock

Mckesson Corporation (MCK) delivered better-than-expected earnings for the last quarter and updated its outlook for fiscal 2023. Wall Street analysts expect the stock to rise more than 18% in the near term. Therefore, it could be wise to buy this medical stock now. Read more….

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Pharma giant tops new business gender equality index

‘Lead5050 Index provides a comprehensive snapshot of how well employers tackle the gender pay gap’

AAP

ASX drug companies applaud TGA's psychedelic ruling

Shares in Little Green Pharma and Emyria are up by more than 40 per cent as both announce plans to take advantage of Australia's "world-leading" drug decision.

Daily Mirror

'Possibly contaminated' eye drops recalled after patient dies of bloodstream infection

A total of 55 patients reported adverse effects after using EzriCare and Delsam Pharma's Artificial Tears, including eye infections, permanent loss of vision, and a death with a bloodstream infection

The Independent UK

‘Thanks Pfizer’: The weird world of shakes, health anxiety and illness online

Eloise Hendy asks psychologists and doctors if the viral wave of vaccine-induced symptoms is real or faked or something else entirely

Pedestrian.tv

MDMA & Psilocybin Can Now Be Prescribed To Treat Certain Mental Health Conditions In Australia

Australia in its progressive drug policy era????? Here for it.

The Guardian - AU

Port Macquarie cleans up after ‘mini-cyclone’ – as it happened

People in NSW town are being urged to stay away from downed power lines. This blog is now closed

Reuters

U.S. FDA says India-made eye drop linked to some infections, blindness and one death

The U.S. Food and Drug Administration (FDA) has warned against using an eye drop made in India that has been linked to the outbreak of a drug-resistant bacteria leading to adverse events in at least 55 patients in the United States including infections, blindness and one death.

1 … 59 60 61 62

People

Joe Biden

68,015 stories

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.